Japanese Takara buys Cellectis stem cell unit
This article was originally published in Clinica
Executive Summary
French immunotherapy company Cellectis has sold off one of its subsidiaries to Japan's Takara Bio for an undisclosed sum as part of a restructuring the company began in 2013.